Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Disorders of Erythrocytes01:27

Disorders of Erythrocytes

Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
Multiple Allele Traits01:49

Multiple Allele Traits

The Concept of Multiple Allelism
Genetic Lingo01:11

Genetic Lingo

Overview
Multipotency of Hematopoietic Stem Cells01:19

Multipotency of Hematopoietic Stem Cells

The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
Erythropoiesis01:14

Erythropoiesis

Red blood cells  (RBCs) transport oxygen to all body tissues. These cells survive only for 120 days and then need to be replenished. Erythropoiesis is the process of RBC production. In healthy individuals, erythropoiesis ensures all tissues are amply supplied with oxygen. In addition, blood loss due to injury leads to a drop in the physiological oxygen level that will cause erythropoiesis. Any defect in erythropoiesis leads to several physiological disorders, including thalassemia, anemia, and...
Hematopoiesis01:21

Hematopoiesis

The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Corrigendum to "'Erythritol', a safe natural sweetener exhibits multi-stage anti-malarial activity by permeating into Plasmodium falciparum through aquaglyceroporin channel" [Biochem. Pharmacol. 205 (2022) 115287].

Biochemical pharmacology·2026
Same author

Red cell shape regulation by band 3-ankyrin-spectrin linkage: implications for clinical severity of bovine hereditary spherocytosis.

Blood. Red cells & iron·2026
Same author

The red blood cell proteome and interactome identify a Band 3-BLVRB axis regulating hypoxic metabolic adaptation.

Blood·2026
Same author

Stag2 dependent chromatin remodeling enforces the erythroid-specific Gata1 cistrome.

Blood·2026
Same author

RPS19 and RPL5 haploinsufficient models reveal divergent ribosomal subunit controls of fetal hematopoiesis.

Nature communications·2026
Same author

Slowing the cell cycle to increase fetal hemoglobin.

Blood·2026
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
関連記事をすべて見る

関連する実験動画

Updated: Jun 28, 2026

Robot-Assisted Laparoscopic Splenectomy In Children: A Case Report with Literature Review
05:06

Robot-Assisted Laparoscopic Splenectomy In Children: A Case Report with Literature Review

Published on: March 27, 2026

遺伝性球球細胞症 遺伝性球球細胞症

Silverio Perrotta1, Patrick G Gallagher, Narla Mohandas

  • 1Department of Paediatrics, Second University of Naples, Naples, Italy.

Lancet (London, England)
|October 23, 2008
PubMed
まとめ
この要約は機械生成です。

遺伝性球球細胞症は一般的な遺伝性貧血であり,赤血球の表面積を減らし,臓での破壊につながります. この遺伝的疾患は,変数性貧血,黄,および臓の拡大を伴い,生活の質に影響を及ぼします.

さらに関連する動画

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

関連する実験動画

Last Updated: Jun 28, 2026

Robot-Assisted Laparoscopic Splenectomy In Children: A Case Report with Literature Review
05:06

Robot-Assisted Laparoscopic Splenectomy In Children: A Case Report with Literature Review

Published on: March 27, 2026

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

科学分野:

  • 血液学 ヘマトロジ
  • 遺伝学 遺伝学とは
  • 分子生物学は分子生物学である.

背景:

  • 遺伝性球球細胞症 (HS) は,世界中で個人に影響を与える一般的な遺伝性貧血です.
  • 北欧系の人たちの中で最も一般的な遺伝性貧血です.
  • HSの特徴は,貧血,黄,腫で,臨床的重度が変動する.

研究 の 目的:

  • 遺伝性球球細胞症の重要な特徴を要約すると.
  • 基礎にある分子欠陥とその結果を解明する.
  • HSの臨床表現,合併症,および管理について議論します.

主な方法:

  • 遺伝性球球細胞症に関する既存の文献のレビュー.
  • 膜タンパク質の遺伝的欠陥の分析.
  • 球球細胞破壊の病理生理学的記述.

主要な成果:

  • HSの主な欠陥は,アンキリン,バンド3,スペクトリンなどのタンパク質の突然変異による赤血球膜表面積の損失を伴う.
  • 異常な球球球細胞は,の中で隔離され,破壊され,血液溶解を引き起こします.
  • 多くの突然変異が存在するが,一般的なHS関連突然変異は特定されていない.

結論:

  • 遺伝性球球細胞症は,赤血球膜タンパク質の遺伝的欠陥によって引き起こされ,特徴的な貧血を引き起こす.
  • スプレネクトミーは治療法を提供しますが,リスク・利益の慎重な評価が必要です.
  • 一般的な合併症には,胆石,血溶性エピソード,およびアプラスティック危機があります.